非酒精性脂肪性肝炎（NASH）由于发病机制并不明确，目前尚无有效的治疗手段。前期研究发现Gb3贮积可导致肝脏脂代谢障碍和炎症细胞聚集。进一步研究提示，Gb3可激活脂滴蛋白HSD17B13，后者通过增强脂肪酸从头合成抑制脂肪酸β氧化，同时HSD17B13可促进白三烯B4生成，触发肝脏炎症反应。本项目基于课题组前期研究肝脏中Gb3蓄积可导致肝脏脂质沉积和炎症反应的研究方向，从细胞水平到动物水平，结合线粒体生物学、靶向代谢组学，13C-NMR同位素分析等多个研究层面和技术手段揭示Gb3贮积在NASH发生发展过程中的作用。阐明Gb3分别激活HSD17B13-ACC2途径和HSD17B13-5-LO-LTB4/BLT-1途径导致肝脏脂代谢障碍和炎症反应参与NASH的发生发展。本课题拟从代谢角度探究NASH发病机制，有望从源头找到导致NASH发病的诱因，为临床治疗提供新的思路及治疗靶点。

The pathogenesis of nonalcoholic fatty liver is not clear, and there is no effective treatment. Our pre-experiment have found that Gb3 storage can lead to liver lipid metabolism disorders and inflammatory cell aggregation. Further studies suggest that Gb3 can activate lipid droplet protein HSD17B13, which inhibits fatty acid β-oxidation by enhancing de novo lipogenesis, and HSD17B13 also promotes the formation of leukotriene B4 to trigger liver inflammation. This project is based on our previous research on the role of Gb3 accumulation in liver lipid deposition and inflammation. The study reveals the role of Gb3 storage in the development of NASH from cell level to animal level, combined with mitochondrial biology, targeted metabolomics and 13C-NMR isotope analysis and elucidates that Gb3 activates HSD17B13-ACC2 pathway and HSD17B13-5-LO-LTB4/BLT-1 pathway respectively, which lead to liver lipid metabolism disorders and inflammation in the development of NASH. This topic intends to explore the pathogenesis of NASH from the metabolic point of view. It is hopeful to find the cause of NASH from the source, and provide new ideas and therapeutic targets for clinical treatment.